title: Ocular therapeutics.
authors.affiliation: g.napper@bigpond.com
authors.forename: Julie
authors.initials: J
authors.lastname: Albietz
authors.forename: Ian
authors.initials: I
authors.lastname: Douglas
authors.forename: Genevieve
authors.initials: G
authors.lastname: Napper
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017963:Azithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D005128:Eye Diseases / Q000188:drug therapy*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D009798:Ocular Hypertension / Q000188:drug therapy; D000069579:Ranibizumab; D012008:Recurrence; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced; D014141:Trachoma / Q000188:drug therapy / Q000209:etiology; D000069557:Travoprost
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003008:Cloprostenol; D017963:Azithromycin; D000069557:Travoprost; D000069579:Ranibizumab